BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 27303043)

  • 1. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
    Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
    Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
    BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
    Smith HW; Hirukawa A; Sanguin-Gendreau V; Nandi I; Dufour CR; Zuo D; Tandoc K; Leibovitch M; Singh S; Rennhack JP; Swiatnicki M; Lavoie C; Papavasiliou V; Temps C; Carragher NO; Unciti-Broceta A; Savage P; Basik M; van Hoef V; Larsson O; Cooper CL; Vargas Calderon AC; Beith J; Millar E; Selinger C; Giguère V; Park M; Harris LN; Varadan V; Andrechek ER; O'Toole SA; Topisirovic I; Muller WJ
    Nat Commun; 2019 Jul; 10(1):2901. PubMed ID: 31263101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
    Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
    Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations and deletions of PRC2 in prostate cancer.
    Jain P; Di Croce L
    Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
    Lawrence CL; Baldwin AS
    PLoS One; 2016; 11(10):e0165005. PubMed ID: 27764181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
    Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W
    Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
    Gautam N; Kaur M; Kaur S
    J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
    Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
    Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 16. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
    Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis.
    Su D; Wang W; Hou Y; Wang L; Yi X; Cao C; Wang Y; Gao H; Wang Y; Yang C; Liu B; Chen X; Wu X; Wu J; Yan D; Wei S; Han L; Liu S; Wang Q; Shi L; Shan L
    Nucleic Acids Res; 2021 May; 49(8):4421-4440. PubMed ID: 33849069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.